These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 29379211)

  • 41. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71.
    Deng YQ; Ma J; Xu LJ; Li YX; Zhao H; Han JF; Tao J; Li XF; Zhu SY; Qin ED; Qin CF
    Appl Microbiol Biotechnol; 2015 Sep; 99(18):7663-71. PubMed ID: 25967656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.
    Rockman S; Camuglia S; Vandenberg K; Ong C; Baker MA; Nation RL; Li J; Velkov T
    Mol Immunol; 2013 Apr; 53(4):435-42. PubMed ID: 23127859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
    Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
    Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.
    Wen X; Mousa JJ; Bates JT; Lamb RA; Crowe JE; Jardetzky TS
    Nat Microbiol; 2017 Jan; 2():16272. PubMed ID: 28134915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.
    Simmons CP; Bernasconi NL; Suguitan AL; Mills K; Ward JM; Chau NV; Hien TT; Sallusto F; Ha do Q; Farrar J; de Jong MD; Lanzavecchia A; Subbarao K
    PLoS Med; 2007 May; 4(5):e178. PubMed ID: 17535101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An augmented passive immune therapy to treat fulminant bacterial infections.
    Rajam G; Sampson J; Carlone GM; Ades EW
    Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):157-67. PubMed ID: 20370679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.
    Stiegler G; Katinger H
    J Antimicrob Chemother; 2003 Apr; 51(4):757-9. PubMed ID: 12654737
    [No Abstract]   [Full Text] [Related]  

  • 50. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
    Clayton AM
    J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.
    Prabhu N; Prabakaran M; Hongliang Q; He F; Ho HT; Qiang J; Goutama M; Lim AP; Hanson BJ; Kwang J
    Antivir Ther; 2009; 14(7):911-21. PubMed ID: 19918095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
    Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
    J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Viral infection].
    Tsutsumi H
    Nihon Rinsho; 2002 Mar; 60(3):585-90. PubMed ID: 11904977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protection Against H7 Subtype Influenza Virus Infection in Mice by Passive Transfer of Neutralizing Monoclonal Antibody.
    Zhang Z; Liu M; Zheng S
    Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):360-5. PubMed ID: 26492625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monoclonal antibody-based genetic immunotherapy.
    Pelegrin M; Gros L; Dreja H; Piechaczyk M
    Curr Gene Ther; 2004 Sep; 4(3):347-56. PubMed ID: 15384948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Passive immunoprophylaxis with human monoclonal antibodies.
    Masuho Y
    Biotechnology; 1992; 20():405-30. PubMed ID: 1600386
    [No Abstract]   [Full Text] [Related]  

  • 57. Return to the past: the case for antibody-based therapies in infectious diseases.
    Casadevall A; Scharff MD
    Clin Infect Dis; 1995 Jul; 21(1):150-61. PubMed ID: 7578724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the native human antibody repertoire to create antiviral therapeutics.
    Dessain SK; Adekar SP; Berry JD
    Curr Top Microbiol Immunol; 2008; 317():155-83. PubMed ID: 17990793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging Strategies for Therapeutic Antibody Discovery from Human B Cells.
    Rajan S; Dall'Acqua WF
    Adv Exp Med Biol; 2020; 1255():221-230. PubMed ID: 32949403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human monoclonal antibodies for infectious diseases.
    Masuho Y
    Acta Paediatr Jpn; 1987 Aug; 29(4):571-3. PubMed ID: 3144894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.